Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus

Table 3

Gender differences in treatment interruption due to adverse events.

	Females, (%)	Males, (%)	value
Chronic or recurring genital yeast infections	37 (21.4)	29 (12.3)	0.020
Persistent or recurring urinary tract infections	7 (4.0)	4 (1.7)	0.216
Other adverse events^a	10 (5.8)	11 (4.7)	0.655
Overall	54 (31.2)	44 (18.7)	0.005

^aPolyuria, nausea, hypotension, dizziness, acute coronary event, worsening of glycemic control, and rapid deterioration of renal function. Statistical analysis was performed using Fisher’s exact test.